Glaxosmithkline Share News (GSK)

BROKER RATINGS SUMMARY: Macquarie Starts Burberry At Outperform

LONDON BRIEFING: Coca-Cola HBC And Standard Life Impress With Results

LONDON MARKET CLOSE: Commodity, Ex-Dividend Stocks Weigh On FTSE 100

LONDON MARKET MIDDAY: NY Called Higher As Ex-Dividends Damp FTSE 100

WINNERS & LOSERS SUMMARY: Investors Warm To Centrica Results

LONDON MARKET OPEN: Ex-Dividends Weigh On FTSE 100 As Centrica Rises

Friday broker round-up

(ShareCast News) - Cambian Group: Berenberg downgrades to hold with a target of 60p. Shaftesbury: Credit Suisse upgrades to outperform with a target price of 945p. Acacia Mining: UBS and Deutsche Bank reiterate buy with a target of 275p and 280p respectively. Ashmore: Citigroup stays at buy with a

TOP NEWS SUMMARY: UK Regulator Fines GlaxoSmithKline GBP38 Million

UPDATE 2-UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals

* CMA says GSK delayed generic competition to Seroxat * GSK disagrees and considering grounds for appeal * Merck KGaA also fined as former parent of generic firm (Adds Merck comment) By Ben Hirschler LONDON, Feb 12 (Reuters) - Britain's competition watchdog has fined Gla

BROKER RATINGS SUMMARY: Investec Upgrades Standard Chartered To Buy

UPDATE 1-UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals

* CMA says GSK delayed generic competition to Seroxat * GSK strongly disagrees, considering grounds for appeal * Merck KGaA also fined as former parent of generic firm (Adds details on other companies and fines, context) By Ben Hirschler LONDON, Feb 12 (Reuters) - Britai

CMA fines GlaxoSmithKline £38m for generics delay scam

(ShareCast News) - The UK competition watchdog has fined GlaxoSmithKline for making illegal payments to rivals that delayed the launch of potentially cheaper generic medicine, potentially costing the NHS many millions. GSK has been fined £37.6m by the Competition and Markets Authority, with Merck fi

GlaxoSmithKline Fined As UK Competition Body Sends "Strong Message"

UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals

LONDON, Feb 12 (Reuters) - Britain's competition body said on Friday it had fined GlaxoSmithKline 37.6 million pounds ($54.42 million) for market abuse in striking deals to delay the launch of generic copies of its antidepressant Seroxat. GSK said it strongly disagreed and argued its action

Dividends Calendar - Week Ahead